stock-detail (IMGN)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

West Cancer Center Chooses Flatiron Health’s OncoEMR® and OncoAnalytics® to Support High Quality Patient Care

3/1/2016 11:04 am

(Flatiron Health) Mar 1, 2016 — Flatiron Health and West Cancer Center today announced that West Cancer Center selected OncoEMR® and OncoAnalytics® to enhance the delivery of high quality evidence-based care, support participation in alternative payment models and better manage clinical workflows.

Some Heart Drugs And Antibiotics Show Effective In Fighting Cancer

2/9/2016 11:04 am

(University of Montreal News) Feb 9, 2016 - North American researchers have identified drugs that showed promising perspectives in treating cancers, according to a recent study published in Cancer Research.

Critical Outcome Technologies Pursues Orphan Drug Designation for COTI-2 Intended to Treat Li-Fraumeni Syndrome

12/2/2015 12:01 pm

(CNNMoney) Dec 2, 2015 - Critical Outcome Technologies Inc. announced today that it submitted an Orphan Drug Application intended for the treatment of Li-Fraumeni Syndrome (LFS) to the U.S. Food and Drug Administration (FDA) for its lead cancer drug candidate, COTI-2.

Led By Biotech Stars, ORIC Nabs $53M To Fight Drug-Resistant Cancer

12/2/2015 12:00 pm

(Xconomy San Francisco) Dec 2, 2015 - Rich Heyman twice made hay developing drugs to treat cancers that depend on hormones to thrive. Now he’s trying it again with a new company markedly different than the previous two.

Guided Therapeutics and FDA Review Team Agree on Path Forward for LuViva® Advanced Cervical Scan PMA Application

12/2/2015 12:00 pm

(Yahoo! Finance) Dec 2, 2015 - Guided Therapeutics, Inc., the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today it believes it has reached a general agreement with the U.S. Food and Drug Administration (FDA) on a plan for submitting an approvable application for the LuViva® Advanced Cervical Scan.

Abcodia Announces Initial U.S. Availability of the ROCA® Test to Aid in the Early Detection of Ovarian Cancer

12/2/2015 12:00 pm

(Abcodia) Dec 2, 2015 - Abcodia Ltd, a clinical stage company engaged in the commercial development of novel tests for the early detection of cancer, announced today the availability of the ROCA® Test for use by physicians in five U.S. states: Arizona, Illinois, Massachusetts, New Jersey and Texas.

Screen-Film Mammography Will Soon be ‘Virtually Obsolete,’ FDA Says

12/2/2015 12:00 pm

(RAPS) Dec 1, 2015 - As quality issues with screen-film mammography continue to crop up, the US Food and Drug Administration (FDA) says facilities are almost done transitioning to full field digital mammography (FFDM) units 15 years after they came into clinical use.

CMS Corrects 2016 Reimbursement Rate for Cologuard®

12/2/2015 12:00 pm

(Yahoo! Finance) Dec 2, 2015 - Exact Sciences Corp. announced that the Centers for Medicare and Medicaid Services (CMS) indicated that it is correcting the 2016 Clinical Laboratory Fee Schedule (CLFS) and will include the reimbursement national limitation amount (NLA) for Cologuard at $493.21.

Preliminary Phase 2 Data Demonstrate Tumor Treating Fields is Safe in Patients with Brain Metastases Originating from Non-Small Cell Lung Cancer

12/2/2015 11:05 am

(TheStreet) Dec 2, 2015 - Preliminary data from COMET, a phase 2 randomized trial sponsored by Novocure, show that the use of Tumor Treating Fields (TTFields) therapy is safe in the treatment of brain metastases originating from non-small cell lung cancer (NSCLC).

Immunovaccine's DPX-Survivac Induces an Immune Response in Diffuse Large B Cell Lymphoma

12/2/2015 11:05 am

(MarketWatch) Dec 2, 2015 - Immunovaccine Inc., a clinical stage vaccine and immunotherapy company, today announced that the initial results from a Phase 2 study demonstrated that DPX-Survivac can induce a strong immune response in diffuse large B cell lymphoma (DLBCL) tumors.

Kite Pharma Initiates the ZUMA-3 Study to Support Registration of KTE-C19 for Relapsed or Refractory (r/r) Acute Lymphoblastic Leukemia (ALL) in Adult Subjects

12/2/2015 11:05 am

(Kite Pharma) Dec 2, 2015 - Kite Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing engineered autologous cell therapy (eACT(TM)) products for the treatment of cancer, today announced that it has initiated a phase 1/2 clinical study of KTE-C19 (ZUMA-3) for the treatment of adult patients with r/r ALL.

OncoGenex Announces Phase 3 AFFINITY Trial with Custirsen Continues Following Interim Analyses

12/2/2015 11:05 am

(MarketWatch) Dec 1, 2015 - Final results expected in second half of 2016.

Boehringer Ingelheim and MD Anderson Join Forces To Discover New Treatment Approaches For Pancreatic Cancer

12/2/2015 11:05 am

(MD Anderson) Dec 2, 2015 - Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a collaboration focused on developing innovative medicines for pancreatic ductal adenocarcinoma (PDAC).

In India, IBM's Watson Will Aid Cancer Care Where Doctors Are Scarce

12/2/2015 11:05 am

(Forbes) Dec 2, 2015 - IBM and a large hospital system in India have partnered to diagnose and treat cancer care in a country of 1.2 billion residents who often cannot access oncologists, leaving their diseases undetected and untreated.

Radiotherapy May Help in Node-Positive Prostate Cancer

12/2/2015 11:04 am

(Medscape/Reuters Health) Dec 2, 2015 - Adding prostate and pelvic radiotherapy (RT) to hormone therapy appears to cut relapse rates in men newly diagnosed with high-risk nonmetastatic (M0) node-positive prostate cancer, according to an exploratory analysis by European investigators.

Cancer Patients May Benefit From Mindfulness-Based Therapy

12/2/2015 11:04 am

(Reuters Health) Nov 30, 2015 - Mindfulness-based therapy may help ease anxiety and depression in some patients with cancer, a small research review suggests.

Novartis Presents New Data On Targeted Combination Therapy At SABCS Reinforcing Commitment To Breast Cancer Patients

12/2/2015 11:04 am

(Novartis) Dec 2, 2015 - Novartis will present data that highlight advancements in targeted combination therapy research, and underscore the company's continued commitment to bringing innovative treatments to patients living with advanced breast cancer at the 2015 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), December 8-12.

How to Know Whether to Believe a Health Study

8/18/2015 12:02 pm

(New York Times/The Upshot) Aug 17, 2015 - One of the chief limitations of randomized trials is that they’re typically focused on narrow populations that meet strict criteria — those most likely to benefit from treatment.

ASCO Updates Guideline for Use of White Blood Cell Growth Factors

7/15/2015 11:04 am

(ASCO) July 13, 2015 - The American Society of Clinical Oncology (ASCO) today issued an update to its 2006 clinical practice guideline on the use of white blood cell growth factors (also known as hematopoietic colony-stimulating factors, CSFs). The agents are given to lower the risk of low white blood cell counts and fever (febrile neutropenia) associated with certain types of chemotherapy.

Vertex Profits Hinge on FDA Approving New Cystic Fibrosis Drug This Week

6/30/2015 12:02 pm

(TheStreet) June 29, 2015 - Vertex Pharmaceuticals is widely expected to win U.S. approval later this week for a new drug which could one day treat almost half of cystic fibrosis patients.

Lipid in Avocados May be Key to Leukemia

6/16/2015 11:05 am

( June 15, 2015 - A molecule derived from avocados targets leukemia stem cells.

ASCO Launches PracticeNET, a Collaborative Reporting Network for Oncology Practices

5/6/2015 11:05 am

(ASCO) May 6, 2015 - The American Society of Clinical Oncology (ASCO) announced today the launch of PracticeNET, a collaborative network in which practices will share and receive insights to enhance their business operations and quality of care. PracticeNET is the first initiative of ASCO’s newly-formed Clinical Affairs Department.

GlobeImmune Announces Opening of Randomized Phase 2 Chordoma Trial at National Cancer Institute

4/22/2015 11:03 am

(NASDAQ) Apr 22, 2015 - GlobeImmune, Inc. today announced that a randomized Phase 2 clinical trial designed to investigate the safety and efficacy of GI-6301 in combination with radiation therapy in patients with chordoma is open for enrollment at the National Cancer Institute (NCI).

AACR, ABC News’ Dr. Richard Besser Use Twitter’s Periscope to Live Stream “Breakthroughs in Cancer Research” From 2015 Annual Meeting

4/22/2015 11:03 am

(AACR) Apr 22, 2015 - The American Association for Cancer Research (AACR) and Richard Besser, MD, ABC News' chief health and medical editor, joined forces Tuesday afternoon on Besser's Twitter chat to share stories, observations, and significant research from the nation's top cancer researchers in conjunction with the AACR Annual Meeting, held April 18 to 22, in Philadelphia.

Seven New Drugs OK'd for NHS Scotland

4/14/2015 12:01 pm

(PharmaTimes [UK]) Apr 13, 2015 - Seven new medicines have been accepted for use by the National Health Service in Scotland, including therapies for leukaemia, lung cancer and multiple sclerosis.